Wireless Device Monitors Oxygen Levels Remotely
|
By HospiMedica International staff writers Posted on 06 Feb 2020 |
|
Image: The wireless Lumee optical reader (Photo courtesy of Profusa)
A novel sensing platform provides continuous, real-time monitoring of tissue oxygen in patients with potential acute and/or chronic changes in tissue oxygen levels.
The Profusa (Emeryville, CA, USA) Wireless Lumee Oxygen platform consists of a tiny biosensor injected in the upper arm, shoulder, or leg for continuous and long-term monitoring of oxygen in subcutaneous tissue; and a low profile, lightweight wireless optical reader that adheres to the skin, which reads the fluorescent signal from the biosensor and transmits the data to a tablet, which displays real-time data visualization using the proprietary Lumee app. The data monitored includes changes in oxygen levels, comparison of the patient's current data with historical data from a clinical registry study, and a data report.
The data outputs allow physicians to monitor compromised tissue in conditions such as peripheral artery disease (PAD) and critical limb ischemia (CLI), as well as to compare a patient's oxygen levels before, during, and after an endovascular procedure. In contrast to external pulse oximeters, which measure oxygen bound to the hemoglobin in larger blood vessels, it measures dissolved oxygen at the tissue level in interstitial fluid. The Lumee Oxygen Platform has received the Conformité Européenne (CE) Mark of approval.
“The more comprehensive and detailed we can make our data, the better we are able to help people living with peripheral artery disease and other serious conditions in which blood flow to the limbs is impeded,” said Ben Hwang, PhD, chairman and CEO of Profusa. “We designed the Wireless Lumee Oxygen Platform to be small and wearable in order to increase its uptake and use. We believe that the Wireless Lumee Oxygen Platform will especially help realize the promise of remote patient monitoring and digital health applications.”
The Profusa biosensor is approximately 5 mm long and 500 microns in diameter, made of a soft, flexible fiber that mimics the 3D microenvironment of cells, helping it overcome local inflammation or rejection. The biosensor contains a smart gel that is linked to a light-emitting molecule; once excited by the optical reader, it emits a fluorescent light that is proportional to the amount of oxygen measured.
Related Links:
Profusa
The Profusa (Emeryville, CA, USA) Wireless Lumee Oxygen platform consists of a tiny biosensor injected in the upper arm, shoulder, or leg for continuous and long-term monitoring of oxygen in subcutaneous tissue; and a low profile, lightweight wireless optical reader that adheres to the skin, which reads the fluorescent signal from the biosensor and transmits the data to a tablet, which displays real-time data visualization using the proprietary Lumee app. The data monitored includes changes in oxygen levels, comparison of the patient's current data with historical data from a clinical registry study, and a data report.
The data outputs allow physicians to monitor compromised tissue in conditions such as peripheral artery disease (PAD) and critical limb ischemia (CLI), as well as to compare a patient's oxygen levels before, during, and after an endovascular procedure. In contrast to external pulse oximeters, which measure oxygen bound to the hemoglobin in larger blood vessels, it measures dissolved oxygen at the tissue level in interstitial fluid. The Lumee Oxygen Platform has received the Conformité Européenne (CE) Mark of approval.
“The more comprehensive and detailed we can make our data, the better we are able to help people living with peripheral artery disease and other serious conditions in which blood flow to the limbs is impeded,” said Ben Hwang, PhD, chairman and CEO of Profusa. “We designed the Wireless Lumee Oxygen Platform to be small and wearable in order to increase its uptake and use. We believe that the Wireless Lumee Oxygen Platform will especially help realize the promise of remote patient monitoring and digital health applications.”
The Profusa biosensor is approximately 5 mm long and 500 microns in diameter, made of a soft, flexible fiber that mimics the 3D microenvironment of cells, helping it overcome local inflammation or rejection. The biosensor contains a smart gel that is linked to a light-emitting molecule; once excited by the optical reader, it emits a fluorescent light that is proportional to the amount of oxygen measured.
Related Links:
Profusa
Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Medical-Grade Display
HL2316SHTB
New
Blood Gas Analyzer
i-Check200
Latest Critical Care News
- Noninvasive Monitoring Device Enables Earlier Intervention in Heart Failure
- Automated IV Labeling Solution Improves Infusion Safety and Efficiency
- First-Of-Its-Kind AI Tool Detects Pulmonary Hypertension from Standard ECGs
- 4D Digital Twin Heart Model Improves CRT Outcomes
- AI Turns Glucose Data Into Actionable Insights for Diabetes Care
- Microscale Wireless Implant Tracks Brain Activity Over Time
- Smart Mask Delivers Continuous, Battery-Free Breath Monitoring
- Routine Blood Pressure Readings May Identify Risk of Future Cognitive Decline
- CGM-Based Algorithm Enhances Insulin Dose Adjustment in Type 2 Diabetes
- Fish Scale–Based Implants Offer New Approach to Corneal Repair
- Dual-Function Wound Patch Combines Infection Sensing and Treatment
- Smartwatch Signals and Blood Tests Team Up for Early Warning on Insulin Resistance
- Smart Fabric Technology Aims to Prevent Pressure Injuries in Hospital Care
- Standardized Treatment Algorithm Improves Blood Pressure Control
- Combined Infection Control Strategy Limits Drug-Resistant Outbreak in NICU
- AI Helps Predict Which Heart-Failure Patients Will Worsen Within a Year
Channels
Artificial Intelligence
view channel
AI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read more
Surgical Techniques
view channel
Ultrasound Technology Aims to Replace Invasive BPH Procedures
Benign prostatic hyperplasia (BPH) is a frequent cause of lower urinary tract symptoms in aging men and often requires invasive procedures or prolonged recovery. With prevalence expected to rise as populations... Read more
Continuous Monitoring with Wearables Enhances Postoperative Patient Safety
Postoperative hypoxemia on general surgical wards is common and often missed by intermittent vital sign checks. Undetected low oxygen levels can delay recovery and raise the risk of complications that... Read more
Patient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Health IT
view channel
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read more
Business
view channel
GE HealthCare Leads Major European Initiative to Advance Cardio-Oncology Care
Cardiovascular complications are increasingly recognized among people undergoing or recovering from cancer treatment, driven by pre‑existing disease and the cardiotoxic effects of chemotherapy, radiotherapy,... Read more
